The dysregulation of TLR4 signalling in diabetes complicated by dyslipidaemia may contribute to the pathogenesis and exacerbation of diabetic neuropathy, and TLR4 can be a therapeutic target for diabetic neuropathy. This evidence concerns the gene TLR4 and diabetes mellitus.